UA93488C2 - Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг - Google Patents

Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг

Info

Publication number
UA93488C2
UA93488C2 UAA200705812A UAA200705812A UA93488C2 UA 93488 C2 UA93488 C2 UA 93488C2 UA A200705812 A UAA200705812 A UA A200705812A UA A200705812 A UAA200705812 A UA A200705812A UA 93488 C2 UA93488 C2 UA 93488C2
Authority
UA
Ukraine
Prior art keywords
antibody
glypican
sugar chain
modified sugar
fucose
Prior art date
Application number
UAA200705812A
Other languages
English (en)
Russian (ru)
Inventor
Кійотака Накано
Ізумі Суго
Масаміті Сугімото
Такахіро Ісігуро
Мегумі Танака
Сігеюкі Іідзіма
Original Assignee
Чугаі Сейяку Кабусікі Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаі Сейяку Кабусікі Кайся filed Critical Чугаі Сейяку Кабусікі Кайся
Publication of UA93488C2 publication Critical patent/UA93488C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Винахід належить до композиції антитіл, які специфічно зв’язують гліпікан-3 (GPC3), частина з яких містить модифікований цукровий ланцюг, де зазначені антитіла або позбавлені фукози, або містять приєднаний дворозсікаючий N-ацетилглюкозамід (GlcNAc). Винахід також належить до способу одержання антитіла до гліпікану -3 за допомогою клітини, яка має зменшену здатність приєднання фукози до цукрових ланцюгів, зокрема з використанням клітини, позбавленої транспортера фукози, а також до протиракового лікарського засобу, який має як активний інгредієнт заявлену композицію антитіл.
UAA200705812A 2004-10-26 2005-10-26 Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг UA93488C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004311356 2004-10-26
PCT/JP2005/020057 WO2006046751A1 (ja) 2004-10-26 2005-10-26 糖鎖改変抗グリピカン３抗体

Publications (1)

Publication Number Publication Date
UA93488C2 true UA93488C2 (uk) 2011-02-25

Family

ID=36227980

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200705812A UA93488C2 (uk) 2004-10-26 2005-10-26 Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг

Country Status (20)

Country Link
US (2) US7867734B2 (uk)
EP (1) EP1816140A4 (uk)
JP (1) JP4794457B2 (uk)
KR (1) KR101296931B1 (uk)
CN (1) CN101068836B (uk)
AU (1) AU2005297772B2 (uk)
BR (1) BRPI0518279A2 (uk)
CA (1) CA2585196C (uk)
CR (1) CR9151A (uk)
HK (1) HK1110335A1 (uk)
IL (1) IL182662A (uk)
MA (1) MA29025B1 (uk)
MX (1) MX2007004593A (uk)
NO (1) NO20072366L (uk)
NZ (1) NZ554940A (uk)
RU (1) RU2451030C2 (uk)
TW (1) TWI468514B (uk)
UA (1) UA93488C2 (uk)
WO (1) WO2006046751A1 (uk)
ZA (1) ZA200703888B (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
JPWO2005017155A1 (ja) * 2003-06-18 2006-10-12 中外製薬株式会社 フコーストランスポーター
EP2314317A3 (en) 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
CN102698267B (zh) 2004-08-24 2017-07-21 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法
BRPI0518279A2 (pt) * 2004-10-26 2008-11-11 Chugai Pharmaceutical Co Ltd anticorpo antiglipicam 3 tendo cadeia de aÇécar modificada
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8680247B2 (en) 2007-07-17 2014-03-25 Medarex, L.L.C. Monoclonal antibodies against glypican-3
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
AR066172A1 (es) * 2007-09-28 2009-07-29 Chugai Pharmaceutical Co Ltd Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica.
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US8229812B2 (en) 2009-01-28 2012-07-24 Headwater Partners I, Llc Open transaction central billing system
US8589541B2 (en) 2009-01-28 2013-11-19 Headwater Partners I Llc Device-assisted services for protecting network capacity
US11985155B2 (en) 2009-01-28 2024-05-14 Headwater Research Llc Communications device with secure data path processing agents
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
AU2015206272B2 (en) * 2014-01-16 2020-12-03 Calysta, Inc. Microorganisms for the enhanced production of amino acids and related methods
EP3141603A4 (en) 2014-05-08 2017-12-27 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
RU2744245C2 (ru) * 2015-08-03 2021-03-04 Кафа Терапьютикс Лимитед Антитело против глипикана-3 и его применение
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
CN108495653A (zh) 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
AU2017235097B2 (en) 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
WO2018038046A1 (ja) 2016-08-22 2018-03-01 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
CN106591371A (zh) * 2016-11-25 2017-04-26 哈尔滨百伊生生物科技有限公司 Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
EP3684413A1 (en) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
BR112021006254A2 (pt) 2018-10-01 2021-07-27 Adicet Bio, Inc. composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
AU2020283742A1 (en) 2019-05-24 2021-09-16 Elixiron Immunotherapeutics (hong Kong) Limited Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof
BR112021023735A2 (pt) 2019-06-05 2022-01-04 Chugai Pharmaceutical Co Ltd Molécula de ligação de sítio de clivagem de anti-corpo
WO2022171100A1 (zh) * 2021-02-10 2022-08-18 江苏先声药业有限公司 Gpc3人源化抗体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0242355A (ja) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd 超音波検査装置
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
WO1993022332A2 (en) * 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
HUP0001136A3 (en) * 1997-02-12 2002-02-28 Chugai Pharmaceutical Co Ltd Remedies for lymphocytic tumors
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
CA2305712A1 (en) * 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural humanized antibody
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
CN1234769C (zh) 2000-09-12 2006-01-04 联合碳化化学及塑料技术公司 含有烯化氧共聚物的聚合物复合材料
EP1331266B1 (en) * 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
JP4336051B2 (ja) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信端末、発呼制限方法及びプログラム
WO2002079255A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
EP2208784B1 (en) * 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
NZ592087A (en) * 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1462799B1 (en) 2001-11-14 2011-01-19 Kabushiki Kaisha Toshiba Ultrasonograph with calculation of ultrasonic wave refraction
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
US20050171339A1 (en) * 2001-12-28 2005-08-04 Izumi Sugo Method of stabilizing protein
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040259150A1 (en) * 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
ES2324029T3 (es) * 2002-05-23 2009-07-29 Sunnybrook And Women's College Health Sciences Centre Diagnostico de carcinoma hepatocelular.
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
WO2004023145A1 (ja) 2002-09-04 2004-03-18 Perseus Proteomics Inc. Ｇｐｃ3の検出による癌の診断方法
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JPWO2005023301A1 (ja) * 2003-09-04 2006-11-02 中外製薬株式会社 胆管癌治療剤および検出薬
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
EP2314317A3 (en) * 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
WO2006016352A1 (en) * 2004-08-08 2006-02-16 Eli Khayat Pharmaceutical compositions for alleviating excess levels of sugar in diabetic patients
US7659374B2 (en) * 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
CN102698267B (zh) 2004-08-24 2017-07-21 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法
BRPI0518279A2 (pt) 2004-10-26 2008-11-11 Chugai Pharmaceutical Co Ltd anticorpo antiglipicam 3 tendo cadeia de aÇécar modificada
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
SI2202245T1 (sl) * 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
WO2009116659A1 (ja) * 2008-03-17 2009-09-24 国立大学法人宮崎大学 抗グリピカン３抗体を用いる肝癌細胞の検出法
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
AU2005297772B2 (en) 2011-06-23
NZ554940A (en) 2010-04-30
EP1816140A1 (en) 2007-08-08
IL182662A (en) 2014-09-30
RU2007119579A (ru) 2008-12-10
MA29025B1 (fr) 2007-11-01
AU2005297772A1 (en) 2006-05-04
KR20070070222A (ko) 2007-07-03
RU2451030C2 (ru) 2012-05-20
TW200621980A (en) 2006-07-01
WO2006046751A1 (ja) 2006-05-04
BRPI0518279A2 (pt) 2008-11-11
CA2585196A1 (en) 2006-05-04
ZA200703888B (en) 2009-11-25
JP4794457B2 (ja) 2011-10-19
NO20072366L (no) 2007-06-21
TWI468514B (zh) 2015-01-11
MX2007004593A (es) 2007-06-22
US7867734B2 (en) 2011-01-11
IL182662A0 (en) 2007-09-20
JPWO2006046751A1 (ja) 2008-05-22
CR9151A (es) 2008-03-18
KR101296931B1 (ko) 2013-08-14
HK1110335A1 (en) 2008-07-11
US20080124330A1 (en) 2008-05-29
CN101068836B (zh) 2013-08-14
CN101068836A (zh) 2007-11-07
US20110033452A1 (en) 2011-02-10
CA2585196C (en) 2015-01-06
EP1816140A4 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
UA93488C2 (uk) Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг
TW200833712A (en) Antibodies against insulin-like growth factor I receptor and uses thereof
WO2007095506A8 (en) Oligosaccharide modification and labeling of proteins
TW200700092A (en) Tigecycline compositions and methods of preparation
MX2010007443A (es) Metodo para tratar anemias de respuesta baja a eritropoyetina.
EA200800269A1 (ru) Пищевые изделия со средствами доставки и способы их получения
WO2003008431A1 (fr) Methode de production d'un derive d'asparagine de chaines des sucres
MX2008012950A (es) Anticuerpos contra el receptor del factor i de crecimiento de tipo insulina y sus usos.
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
IL191617A (en) An antibody linked to polyubiquitin, a method for its preparation, a pharmaceutical preparation containing it and its uses
EA200401325A1 (ru) Клетки с модифицированным геномом
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
DK1898721T3 (da) Fremgangsmåde til fremstilling af en vandig suspension og et pulverformigt præparat af et eller flere carotioider
CY1106902T1 (el) Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης
WO2007028154A3 (en) Encapsulated arsenic drugs
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2010006173A3 (en) Mineral amino acid polysaccharide complex
DE602006017724D1 (de) Salicylsäurederivate
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2007039317A3 (en) Plants having an increased content of amino sugars
NZ590089A (en) Conjugated vi saccharides
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies
WO2006122777A3 (de) Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
WO2008110374A3 (de) Pellets enthaltend pharmazeutische substanz, verfahren zu deren herstellung und deren verwendung
WO2010121208A3 (en) New methods of making an antibody and compositions thereof